Advanced Search
Contact | Corporate | Help

Phase I/II Study of LBH589 & Erlotinib for Advanced Aerodigestive Tract Cancers

Sponsors:
  • H. Lee Moffitt Cancer Center and Research Institute
  • Genentech
  • Novartis
Phases:
  • Phase I
  • Phase II
IndicationsAcronym:
  • Lung Cancer
  • Head and Neck Cancer
Age Groups:
  • Adult
  • Senior
Gender:
Both
Names:
  • Drug: LBH589
  • Drug: erlotinib
Enrollment:
44

Additional information about NCT00738751.


SourceSolution © 2008-2012